TABLE 1.

Demographics, PD‐related information, and prevalence of post–COVID‐19 syndrome (n = 27); Data is presented as mean ± standard deviation, median (interquartile range) or number (percentage)

Outcome measures	Results
Sex, male	16 (59.3%)
Race/ethnicity
White	9 (33.3%)
Black	2 (7.4%)
Other	16 (59.3%)
Age at PD diagnosis, years	59.0 ± 12.7
PD disease duration at time of COVID‐19 diagnosis, years	9.2 ± 7.8
H&Y stage at COVID‐19 diagnosis	2.0 (1.0)
LEDD at COVID‐19 diagnosis, mg	1053.5 ± 842.4
Hospitalization due to COVID‐19	6 (22.2%)
Charlson Comorbidity Index at COVID‐19 diagnosis	2.0 (1.5)
Post–COVID‐19 syndrome	23 (85.2%)
Respiratory symptoms
Breathlessness	1 (3.7%)
Cough	3 (11.1%)
Cardiovascular symptoms
Chest tightness	0 (0%)
Chest pain	1 (3.7%)
Palpitations	0 (0%)
Generalized symptoms
Fatigue	11 (40.7%)
Fever	5 (18.5%)
Pain	3 (11.1%)
Neurological symptoms
Cognitive disturbances a	6 (22.2%)
Headache	5 (18.5%)
Sleep disturbances	6 (22.2%)
Peripheral neuropathy symptoms b	3 (11.1%)
Dizziness	4 (14.8%)
Delirium	2 (7.4%)
Gastrointestinal symptoms
Abdominal pain	0 (0%)
Nausea	2 (7.4%)
Diarrhea	0 (0%)
Reduced appetite	1 (3.7%)
Musculoskeletal symptoms
Joint pain	3 (11.1%)
Muscle pain	2 (7.4%)
Psychological/psychiatric symptoms
Depression	2 (7.4%)
Anxiety	4 (14.8%)
Ear, nose, and throat symptoms
Tinnitus	0 (0%)
Earache	0 (0%)
Sore throat	0 (0%)
Loss of taste or smell	4 (14.8%)
Dermatological
Skin rashes	0 (0%)
PD‐specific aspects
Motor worsening	14 (51.9%)
Increased LEDD requirement	13 (48.2%)

^aBrain fog, loss of concentration, or memory issues.

^bPins and needles and numbness.

Abbreviations: PD, Parkinson's disease; COVID‐19, coronavirus disease 2019; SD, standard deviation; IQR, interquartile range; H&Y, Hoehn and Yahr Scale; LEDD, levodopa equivalent daily dose.